Agree huge potential for AML treatment, those sellers over past few months were mainly because of trial uncertainty post trial death not directly related to our drug but that is almost fully resolved with only one more trial needing FDA approval to resume. Should be be resolved before years end imo.
None of the board (6% ownership) and institutions (36% ownership) have sold down as we are undervalued compared to peers for the trials we are undertaking. Christmas rally over 10c is on the cards imo.
PTX Price at posting:
6.6¢ Sentiment: Buy Disclosure: Held
